NCT03432741 2025-05-26
Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
Mayo Clinic
Phase 1 Terminated
Mayo Clinic
University of Utah
Sunnybrook Health Sciences Centre
University of Utah
Washington University School of Medicine
Jonsson Comprehensive Cancer Center
Stanford University
Stanford University
Washington University School of Medicine
Virginia Commonwealth University
National Cancer Institute (NCI)
Stanford University